Abstract 4210
Background
Gastrointestinal stromal tumors (GISTs) patients (pts) who develop resistance to imatinib and sunitinib have few therapeutic options. Apatinib is a multiple tyrosine kinase inhibitor and targetsVEGFR2, PDGFRβ and c-Kit, which is effective in several solid tumors. We aimed to assess the efficacy and safety of apatinib in pts with advanced GISTs who failed previous standard tyrosine kinase inhibitors.
Methods
In this single-arm, open-label, phase II study, we enrolled pts (aged ≥18 years) with advanced GISTs resistant to imatinib and sunitinib from 3 comprehensive cancer centers or university hospitals in China and assigned them to 500 mg oral apatinib once daily in 4-week cycles. Pts were assessed for response by RECIST 1.1 every 2 cycles. The primary endpoint was investigator-assessed progression-free survival. The secondary endpoints included response rate, overall survival and advent events.
Results
Between September 2017 and February 2019, 10 pts were enrolled (7 evaluable for response), and pts are still being accrued to the trial. Here we present the preplanned early analysis of clinical outcomes. The median follow-up was 16.6 months. Four pts reached stable disease. The median PFS was 5.4 months (95% CI 2.0–9.8), and the 4-month PFS rate was 57.1%. Drug-related adverse events were reported in 9 (90%) pts and the most common apatinib-related adverse events of grade 3 or higher were hypertension (3 of 10, 30%), hand-foot skin reaction (4 of 10, 40%), fatigue (5 of 10, 50%) and proteinuria (2 of 10, 20%). There was no treatment-related death.
Conclusions
Apatinib appears to have promising anti-tumor activity and an acceptable toxicity profile in pts with advanced GISTs previously treated with imatinib and sunitinib. Apatinib warrants further investigation in GISTs.
Clinical trial identification
ChiCTR1800020407.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chinese Society of Clinical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2490 - Gender effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of anamorelin (ANAM) in healthy volunteers and cancer patients with cachexia
Presenter: Stein Kaasa
Session: Poster Display session 1
Resources:
Abstract
4294 - The Patient Voice: An Irish Survey of Nutrition Attitudes & Access to Dietetic Care Throughout the Cancer Journey
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
1925 - Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients
Presenter: Claudio Chini
Session: Poster Display session 1
Resources:
Abstract
4701 - Treatment-related adverse events and tolerability in patients with advanced non-squamous non-small cell lung cancer treated with first-line checkpoint inhibitors in combination with chemotherapy
Presenter: Ruth D'cunha
Session: Poster Display session 1
Resources:
Abstract
2985 - Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy.
Presenter: Jwa Hoon Kim
Session: Poster Display session 1
Resources:
Abstract
2358 - Physicians’ satisfaction with Health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients.
Presenter: Guillaume Mouillet
Session: Poster Display session 1
Resources:
Abstract
5172 - Predictors of Survival in Patients with Incurable Cancer
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
2281 - Patients and Physicians' Satisfaction with Telemedicine (TM) in Cancer Care and Factors that Correlate with a Positive Patient’s Experience
Presenter: Hurria Gondal
Session: Poster Display session 1
Resources:
Abstract
2193 - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: real-world insights from practicing European physicians
Presenter: Alex Rider
Session: Poster Display session 1
Resources:
Abstract
2200 - Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark
Presenter: Anders Boysen
Session: Poster Display session 1
Resources:
Abstract